

Board Changes

Adelaide: 21 August, 2014: Australian IVF-focused company Reproductive Health Science (RHS) (ASX: RHS) is pleased to announce the appointment of Ms Sue MacLeman as Non-Executive Director.

Sue MacLeman (*BPharm, MMktg, MLaw, FACPP, FAICD*) has enjoyed a distinguished career in biotechnology and brings a wealth of industry experience to the company. Ms MacLeman worked initially in hospital pharmacy roles before moving to the pharmaceuticals industry in development and commercialisation roles with Merck, Amgen and Bristol-Myers Squibb. She has also been CEO and a Board member of a number of publicly-listed companies in both the United States and Australia. Ms MacLeman is a member of the Pharmaceutical Industry Council and the Australian Government Pharmaceutical Industry Working Group. In 2011 she was appointed to the Victorian Biotechnology Advisory Council.

"We are extremely pleased to have Sue involved in what is a very important and exciting stage of the company's development, particularly with her expertise in commercialisation," RHS Chairman Dr David Brookes said.

Ms MacLeman said *"I'm delighted to join the company at such a pivotal stage following the recent launch of EmbryoCollect™ and to be part of that growth opportunity."*

Resignation of Mr Simon O'Loughlin

Mr Simon O'Loughlin has resigned as a director effective immediately to focus on other business commitments. The resignation of Mr O'Loughlin is part of a planned transition following the reverse takeover of AO Energy by RHS. Donald Stephens remains in the Executive Director role of Chief Financial Officer and Company Secretary.

Dr Brookes thanked Mr O'Loughlin for his contribution on behalf of the Company and the Board.

"The successful listing of RHS on the ASX was largely due to Simon's instrumental support last year. We are grateful for his involvement and wish him well with his other many interests," Dr Brookes said.

For further information please contact:

Dr Michelle Fraser

CEO and Managing Director Tel: (+61 8) 8152 9380
michelle.fraser@rhsc.com.au

Reproductive Health Science Ltd.

ACN 010 126 708
ASX: RHS

Issued Capital

51.13 million shares
5.88 million options

Registered Office

Level One, BioSA
Incubator,
40-46 West Thebarton
Road,
Thebarton, SA 5031

Directors

Dr David Brookes (Chairman)
Sue MacLeman
Johnathon Matthews
Donald Stephens
Dr Michelle Fraser (CEO)

Finance Officer

& Company Secretary
Donald Stephens

Tel: +61 8 8152 9380
Fax: +61 8 8152 9474

WEB www.rhsc.com.au

Simon Hinsley

Investor Relations

Tel: (+61 0)401 809 653

simon@nwrcommunications.com.au

About Reproductive Health Science

Reproductive Health Science is an advanced biotech company that has successfully developed a test to assess embryos for chromosomal abnormalities prior to implantation as part of an In-Vitro Fertilisation (IVF) cycle. The two component system has an immediate application to improve the success rate of IVF. The Company's lead product EmbryoCollect™ is aimed at improving health and research outcomes through the application of its frontier technologies with the initial primary focus of improving IVF success. The Company launched this product in mid-2014 and anticipates first sales within the calendar year.